Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hepatitis B virus (HBV) antigen production and viral replication. By reducing viral antigens, host immune reconstitution against HBV may also be attained. Phase I/II trials on siRNAs have demonstrated them to be safe and well-tolerated. siRNA is effective when given in monthly doses with different total number of doses according to different trial design, and can lead to sustainable dose-dependent mean HBsAg reduction by 2–2.5 log. Incidences of HBsAg seroclearance after siRNA therapy have also been reported. ASOs have also been studied in early phase trials, and a phase Ib study using frequent dosing regimen within 4 weeks could achieve similar HBsAg reduction of 2 log from baseline. Given the established efficacy and safety of nucleos(t) ide analogues (NAs), future RNAi regimens will likely include NA backbone. While the current evidence on RNAi appears promising, it remains undetermined whether the potent HBsAg reduction by RNAi can result in a high rate of HBsAg seroclearance with durability. Data on RNAi from phase IIb/III trials are keenly anticipated.
Citations
Citations to this article as recorded by
Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen Gut.2026; 75(1): 119. CrossRef
Functional cure for chronic hepatitis B: A state of immune control over cccDNA persistence Kunyu Zhao, Lili Wu, Yu Wu, Qianqian Jiang, Mengmeng Zhu, Suzhen Jiang, Chao Zhang, Fengmin Lu Infectious Diseases & Immunity.2026; 6(2): 148. CrossRef
Individualising endpoints in chronic HBV treatment: HBsAg loss and beyond Milan J. Sonneveld, Harry L.A. Janssen Journal of Hepatology.2026; 84(4): 823. CrossRef
Update on combination therapies against HBV in clinical investigations Lung-Yi Mak, Anna SF. Lok Antiviral Research.2026; 245: 106321. CrossRef
Targeting the innate immune system in treating hepatitis B: prospects for functional cure Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Clinical and Molecular Hepatology.2026; 32(1): 184. CrossRef
Direct Viral Mechanisms Underlying the Onset of HBV-Related Hepatocellular Carcinoma and Implications for Therapeutic Strategies Simone La Frazia, Alessia Magnapera, Lorenzo Piermatteo, Stefano D’Anna, Leonardo Duca, Valentina Svicher, Romina Salpini Viruses.2026; 18(2): 185. CrossRef
Prevention and treatment of HBV infection-related hepatic fibrosis, cirrhosis, and hepatocellular carcinoma: A research progress review Ying Zhang, Guo-Shun Zhang, Jia-Yi Li, Yi-Xuan Li, Dong-Xue Mei, Ying-Ying Xin, Chao Han, Zheng Shi, Mei-Yu Jiang, Su-Ying Wang World Chinese Journal of Digestology.2026; 34(4): 302. CrossRef
Functionalized locked nucleic acid system for targeted inhibition of hepatitis B virus C gene in transgenic models Wu-Jun Wei, Huai-Jun Luo, Liu-Mei Qin, Jin-Ling Li, Nuo Zhou, Cai-Xia Ling, Jun-Xia Pu, Yi-Bin Deng Arabian Journal of Chemistry.2026; 19: 2382026. CrossRef
Recombinant polyclonal antibody GIGA-2339 potently and pan-genotypically neutralizes hepatitis B virus Sheila M. Keating, Brett W. Higgins, Rena A. Mizrahi, Ariel R. Niedecken, Michael A. Asensio, Peyton Witte, Ashley Gras, Ilana Segal, Sabrina M. Nelson, Yao Chiang, Hongjun Yue, Yibing Yang, Sharda Raina, Yesenia C. Lopez, Julie Lucifora, Angélica Medina Antiviral Research.2026; 253: 106486. CrossRef
Hepatitis B surface antigen clearance rate with pegylated interferon-α therapy in different chronic hepatitis B virus infection populations: A systematic review and meta-analysis Chengrun Song, Yalin Yin, Jingwen Feng, Yujing Li, Min He, Yonghong Wang, Menglan Wang, Yachao Tao, Taoyou Zhou, Fang He, Jiajie Lu, Wei Jiang, Dongbo Wu, Hong Tang, Xuezhong Lei, Enqiang Chen Chinese Medical Journal.2026;[Epub] CrossRef
RNA nanomedicine in liver diseases Anita Bakrania, Yulin Mo, Gang Zheng, Mamatha Bhat Hepatology.2025; 81(6): 1847. CrossRef
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989 Lung Yi Mak, Christine I Wooddell, Oliver Lenz, Thomas Schluep, James Hamilton, Heather L Davis, Xianhua Mao, Wai-Kay Seto, Michael Biermer, Man-Fung Yuen Gut.2025; 74(3): 440. CrossRef
Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA Jihua Ren, Shengtao Cheng, Fang Ren, Huiying Gu, Daiqing Wu, Xinyan Yao, Ming Tan, Ailong Huang, Juan Chen Genes & Diseases.2025; 12(1): 101215. CrossRef
Investigational RNA Interference Agents for Hepatitis B Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen BioDrugs.2025; 39(1): 21. CrossRef
Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy” Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen Journal of Hepatology.2025; 82(5): e228. CrossRef
Inhibition of Hepatitis B Virus Replication by a Novel GalNAc–siRNA In Vivo and In Vitro Zhipeng Zhang, Yanqin Ma, Yan He, Dong Wang, Kun Yue, Xiaomei Zhang, Huaien Song ACS Omega.2025; 10(1): 484. CrossRef
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases Zhen-Xin Qin, Ling Zuo, Ziran Zeng, Rongguan Ma, Wenyan Xie, Xiao Zhu, Xiaorong Zhou Expert Opinion on Drug Delivery.2025; 22(4): 455. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients? Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Hepatology International.2025; 19(2): 304. CrossRef
Prospect of emerging treatments for hepatitis B virus functional cure Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2025; 31(Suppl): S165. CrossRef
Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0 Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Clinical and Molecular Hepatology.2025; 31(Suppl): S134. CrossRef
CTLA4 modulates B cell receptor signals to inhibit HBsAb secretion in chronic hepatitis B patients Shengxia Yin, Minxin Mao, Linyan Gong, Yijia Zhu, Yawen Wan, Xin Tong, Jian Wang, Guiyang Wang, Yong Liu, Chao Wu, Rui Huang, Yuxin Chen Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(6): 167848. CrossRef
Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine Yaru Shi, Rong Fan Interdisciplinary Medicine.2025;[Epub] CrossRef
Advances in the management of hepatitis B Ruma Rajbhandari, Vy H Nguyen, Abigail Knoble, Gregory Fricker, Raymond T Chung BMJ.2025; 389: e079579. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Hepatology International.2025; 19(4): 704. CrossRef
Targeting HBV with RNA interference: Paths to cure Matteo Iannacone, Cristian G. Beccaria, Lena Allweiss, Julie Lucifora, John E. Tavis, Adam J. Gehring, Maura Dandri Science Translational Medicine.2025;[Epub] CrossRef
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure Ana Verma, Raymond T. Chung Current Opinion in HIV and AIDS.2025; 20(5): 449. CrossRef
Virological Insights from ARC-520 siRNA and Entecavir Treated Chronically HBV-Infected Patients and Chimpanzees Christine I. Wooddell, Lung Yi Mak, Wai-Kay Seto, Bruce D. Given, Man-Fung Yuen Microorganisms.2025; 13(8): 1787. CrossRef
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D Junjie Liu, Tong Yuan, Lin Xue, Huifang Liang Virology Journal.2025;[Epub] CrossRef
Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B Lu Zhang, Yu Cao, Sijing Zhuang, Jingjing Sun, Qiao Tong, Jianjun Xi, Shourong Liu, Rangxiao Zhuang Frontiers in Pharmacology.2025;[Epub] CrossRef
Hepatitis B functional cure: Current and future perspective Sudheer Marrapu, Jinit R Soni, Kislaya Kamal, Ramesh Kumar World Journal of Hepatology.2025;[Epub] CrossRef
Strategies to Achieve Functional Cure in HBV: Focus on siRNA Eyyel Karthikeyan, Robert G. Gish Current Hepatology Reports.2025;[Epub] CrossRef
In-Silico Development of Effective Short Hairpin RNA Molecules Targeting the Transactivator Region of Human Hepatitis B Virus Amir Pouremamali, Mehrdad Ravanshad, Leila Asadi Samani, Farhad Pouremamali, Reza Ghanbari Jundishapur Journal of Microbiology.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao Hepatoma Research.2025;[Epub] CrossRef
Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy Xiao‐Tong Li, Shu‐Yi Peng, Shao‐Mei Feng, Ting‐Yu Bao, Sheng‐Zhang Li, Shi‐Ying Li Small.2024;[Epub] CrossRef
Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics Jie-Li Hu, Ai-Long Huang Virologica Sinica.2024; 39(1): 9. CrossRef
Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo Elena M. Smekalova, Maria G. Martinez, Emmanuel Combe, Anuj Kumar, Selam Dejene, Dominique Leboeuf, Chao-Ying Chen, J. Robert Dorkin, Lan Shuan Shuang, Sarah Kieft, Lauren Young, Luis Alberto Barrera, Michael S. Packer, Giuseppe Ciaramella, Barbara Teston Molecular Therapy Nucleic Acids.2024; 35(1): 102112. CrossRef
Can Radionuclide Therapy be the Solution for Hepatitis B Virus Infection? Pil Soo Sung, Ie Ryung Yoo Nuclear Medicine and Molecular Imaging.2024; 58(5): 255. CrossRef
Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161 Angela M. Lam, Ravi R. Dugyala, Muhammed Sheraz, Fei Liu, Emily P. Thi, Ingrid E. Graves, Andrea Cuconati, Holly Micolochick Steuer, Andrzej Ardzinski, Nathan Overholt, Jeremy D. Mason, Dimitar Gotchev, Andrew G. Cole, Troy O. Harasym, Michael J. Sofia Viruses.2024; 16(3): 323. CrossRef
Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model Ellen Van Gulck, Nádia Conceição-Neto, Liese Aerts, Wim Pierson, Lore Verschueren, Mara Vleeschouwer, Vinod Krishna, Isabel Nájera, Frederik Pauwels Viruses.2024; 16(3): 347. CrossRef
Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang World Journal of Gastroenterology.2024; 30(10): 1295. CrossRef
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873 Darryl Kato, Regina Wai-Yan Choy, Eda Canales, Ryan A. Dick, April D. Lake, Nathan D. Shapiro, Elbert Chin, Jiayao Li, Jennifer R. Zhang, Qiaoyin Wu, Roland D. Saito, Sammy Metobo, Evangelos Aktoudianakis, Scott D. Schroeder, Zheng-Yu Yang, Dylan M. Glatt ACS Medicinal Chemistry Letters.2024; 15(4): 546. CrossRef
Model‐based meta‐analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B‐infected mice Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan‐Jose Perez‐Ruixo CPT: Pharmacometrics & Systems Pharmacology.2024; 13(5): 729. CrossRef
Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents Robert Lam, Joseph K Lim World Journal of Hepatology.2024; 16(3): 331. CrossRef
Prospects for Controlling Hepatitis B Globally Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza Pathogens.2024; 13(4): 291. CrossRef
Therapeutic advances in HBV cure Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen Clinical Liver Disease.2024;[Epub] CrossRef
Genotyping Hepatitis B virus by Next-Generation Sequencing: Detection of Mixed Infections and Analysis of Sequence Conservation Eva Dopico, Marta Vila, David Tabernero, Josep Gregori, Ariadna Rando-Segura, Beatriz Pacín-Ruíz, Laura Guerrero, Itziar Ubillos, Miguel J. Martínez, Josep Costa, Josep Quer, Javier Pérez-Garreta, Alejandra González-Sánchez, Andrés Antón, Tomás Pumarola, International Journal of Molecular Sciences.2024; 25(10): 5481. CrossRef
Analysis of the pharmacokinetics and efficacy of RBD1016 – A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model Qian Li, Taohua Geng, Haiyan Li, Shuquan Zheng, Sara Svedlund, Liming Gan, Ann-Charlotte Egnell, Shan Gao, Rui Chen, Pei Hu Heliyon.2024; 10(11): e31924. CrossRef
Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection Wenjing Zai, Min Yang, Kuan Jiang, Juan Guan, Huijing Wang, Kongying Hu, Chao Huang, Jieliang Chen, Wei Fu, Changyou Zhan, Zhenghong Yuan Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library Biplav Shrestha, Sisi Yang, Lauren Griffith, Julia Ma, Fuxuan Wang, Hui Liu, Qiong Zhao, Yanming Du, Jiming Zhang, Jinhong Chang, Ju-Tao Guo Antiviral Research.2024; 228: 105955. CrossRef
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim Clinical and Molecular Hepatology.2024; 30(3): 539. CrossRef
Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain Lanlan Liu, Haoyu Wang, Lulu Liu, Fang Cheng, Haji Akber Aisa, Changfei Li, Songdong Meng Viruses.2024; 16(7): 1151. CrossRef
The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy Mingming Zhang, Han Chen, Huan Liu, Hong Tang Biomarker Research.2024;[Epub] CrossRef
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study Man-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, Tien-Huey Lim, Jeong Heo, Pisit Tangkijvanich, Won Young Tak, Vaidehi Thanawala, Daniel Cloutier, Shenghua Mao, Andre Arizpe, Andrea L Cathcart, Sneha V Gupta, Carey Hwang, Edward Gane The Lancet Gastroenterology & Hepatology.2024; 9(12): 1121. CrossRef
Novel NTCP ligand dimeric bile acid conjugated with ASO reduce hepatitis B virus surface antigen in vivo Lei Lu, Dezi Cong, Tinghong Lv, Haisheng Wang, Xiaolei Wang European Journal of Medicinal Chemistry.2024; 280: 116955. CrossRef
Chitosan/siRNA nanoparticles targeting PARP-1 attenuate Neuroinflammation and apoptosis in hyperglycemia-induced oxidative stress in Neuro2a cells Moqbel Ali Moqbel Redhwan, Hariprasad M.G., Suman Samaddar, Duaa Abdullah Bafail, Sumaia Abdulbari Ahmed Ali Hard, Sourav Guha International Journal of Biological Macromolecules.2024; 282: 136964. CrossRef
A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses Mohadeseh Hasanpourghadi, Mikhail Novikov, Robert Ambrose, Arezki Chekaoui, Dakota Newman, ZhiQuan Xiang, Andrew D. Luber, Sue L. Currie, XiangYang Zhou, Hildegund C.J. Ertl JCI Insight.2024;[Epub] CrossRef
Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates Linh Nguyen, Tiep Tien Nguyen, Ju-Yeon Kim, Jee-Heon Jeong Journal of Nanobiotechnology.2024;[Epub] CrossRef
Utilizing Engineered Bacteria as “Cell Factories” In Vivo for Intracellular RNA-Loaded Outer Membrane Vesicles’ Self-Assembly in Tumor Treatment Dawei Sun, Yize Li, Xiaoxuan Yin, Yali Fan, Jing Liu, Yaxin Wang, Xinyu Liu, Guijie Bai, Ke Li, Yanyan Shi, Peiyuan Liu, Yingying Zhang, Hanjie Wang ACS Nano.2024; 18(52): 35296. CrossRef
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants Haiyan Li, Xiaoye Niu, Yu Zhang, Danning Zhang, Yanqing Zhang, Liqun Wang, Yongqing Miao, Yanxin Jiang, Jia Ji, Qiaoqiao Chen, Xiaoyun Wu, Emmanuel Njumbe Ediage, Thomas N. Kakuda, Michael Biermer Clinical Pharmacology in Drug Development.2023; 12(2): 175. CrossRef
Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow! David Durantel Antiviral Research.2023; 210: 105515. CrossRef
New Approaches to Chronic Hepatitis B Dan L. Longo, Geoffrey Dusheiko, Kosh Agarwal, Mala K. Maini New England Journal of Medicine.2023; 388(1): 55. CrossRef
The scientific basis of combination therapy for chronic hepatitis B functional cure Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 238. CrossRef
Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review Jie-Li Hu, Ai-Long Huang Microorganisms.2023; 11(3): 600. CrossRef
Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui The Lancet Regional Health - Western Pacific.2023; 35: 100738. CrossRef
The progress of molecules and strategies for the treatment of HBV infection Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen, James Fung Expert Review of Gastroenterology & Hepatology.2023; 17(5): 443. CrossRef
Current and novel modalities for management of chronic hepatitis B infection Iman Ibrahim Salama, Samia M Sami, Somaia I Salama, Ghada A Abdel-Latif, Fatma A Shaaban, Walaa A Fouad, Aida M Abdelmohsen, Hala M Raslan World Journal of Hepatology.2023; 15(5): 585. CrossRef
Past, present, and future of long-term treatment for hepatitis B virus Teresa Broquetas, José A Carrión World Journal of Gastroenterology.2023; 29(25): 3964. CrossRef
Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers Lung-Yi Mak, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen Clinics in Liver Disease.2023; 27(4): 877. CrossRef
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease Pavel Strnad, Javier San Martin Expert Opinion on Investigational Drugs.2023; 32(7): 571. CrossRef
Chronic Hepatitis B Infection: New Approaches towards Cure Mojisola Ogunnaike, Srijanee Das, Samiksha S. Raut, Ashrafi Sultana, Mohammad Ullah Nayan, Murali Ganesan, Benson J. Edagwa, Natalia A. Osna, Larisa Y. Poluektova Biomolecules.2023; 13(8): 1208. CrossRef
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen Expert Opinion on Investigational Drugs.2023; 32(11): 971. CrossRef
Cell-Penetrating Peptides as Vehicles for Delivery of Therapeutic Nucleic Acids. Mechanisms and Application in Medicine Ekaterina D. Timotievich, Igor P. Shilovskiy, Musa R. Khaitov Biochemistry (Moscow).2023; 88(11): 1800. CrossRef
Gene-Editing and RNA Interference in Treating Hepatitis B: A Review Nadiia Kasianchuk, Krystyna Dobrowolska, Sofiia Harkava, Andreea Bretcan, Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, Robert Flisiak, Piotr Rzymski Viruses.2023; 15(12): 2395. CrossRef
Peptide carriers as delivery vehicles for therapeutic nucleic acids. Мechanisms and potential applications in medicine E. D Timotievich, I. P Shilovskiy, M. R Khaitov Биохимия.2023; 88(11): 2183. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials Rex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, Man-Fung Yuen Expert Opinion on Emerging Drugs.2022; 27(2): 127. CrossRef
Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection Ilaria Montali, Andrea Vecchi, Marzia Rossi, Camilla Tiezzi, Amalia Penna, Valentina Reverberi, Diletta Laccabue, Gabriele Missale, Carolina Boni, Paola Fisicaro Biomedicines.2022; 10(6): 1224. CrossRef
Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B Mark A. Feitelson, Alla Arzumanyan, Ira Spector, Arvin Medhat Biomedicines.2022; 10(9): 2210. CrossRef
Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection Rex Wan-Hin Hui, Lung-Yi Mak, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen Current Hepatology Reports.2022; 21(4): 59. CrossRef
State-of-the-art and emerging antivirals for chronic hepatitis B infection Margarita Papatheodoridi, George V. Papatheodoridis Expert Opinion on Pharmacotherapy.2022; 23(18): 1999. CrossRef
First
Prev
